- active not recruitingPHASE3
Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
This study looks at a drug called Olaparib for women with a specific type of ovarian cancer. It's for those whose cancer has improved after chemotherapy and have a change in their BRCA gene. We want to see if Olaparib helps keep the cancer away longer.
United States · Australia · Belgium - active not recruitingPHASE2
OSE2101 Alone or in Combination With Pembrolizumab vs BSC in Patient With Platinum-sensitive Recurrent OC
This study looks at new treatments for recurrent ovarian cancer that has responded to previous platinum-based chemotherapy. It compares a vaccine (OSE2101) alone, or with another drug (Pembrolizumab), against standard supportive care to see if they can delay the cancer returning.
Belgium · France · Germany - recruitingPHASE2
Adaptive ChemoTherapy for Ovarian Cancer in Patients With Replased Platinum-sensitive High Grade Serous or High Grade Endometrioid Ovarian Cancer
This study is for women with ovarian cancer that has come back, specifically a type that has responded well to chemotherapy in the past. It's looking at a new way to give carboplatin, a common chemotherapy drug, to see if it can work better and with fewer side effects.
United Kingdom